Full Breakdown
Understanding the Cicada COVID-19 Variant: BA.3.2
3/28/2026, 9:55:32 PM
Overview of the Cicada Variant
The COVID-19 variant known as BA.3.2, informally dubbed "Cicada," has emerged as a significant concern for public health officials globally. First identified in South Africa in November 2024, it remained largely undetected until it began to circulate more widely in September 2025. As of February 2026, the variant has been reported in at least 25 U.S. states and over 23 countries, including Germany, Denmark, and the Netherlands, where it accounts for approximately 30% of cases.
Key Characteristics of BA.3.2
Cicada is characterized by an unusually high number of mutations—between 70 and 75—particularly in its spike protein, which is crucial for the virus's ability to enter human cells. This extensive mutation profile raises concerns about the variant's potential to evade immunity from previous infections or vaccinations. Despite these mutations, early data suggest that BA.3.2 does not appear to cause more severe illness than other circulating variants.
Symptoms Associated with the Cicada Variant
The symptoms of the Cicada variant are largely consistent with those of previous COVID-19 strains. Common symptoms include:
- Cough
- Sore throat (notably reported as more severe in some cases)
- Fever or chills
- Fatigue
- Headache
- Congestion or runny nose
- Changes in taste or smell
Vaccine Effectiveness and Public Health Implications
Current vaccines are expected to provide protection against severe illness caused by BA.3.2, although their effectiveness in preventing infection may be reduced due to the variant's mutations. Health experts emphasize the importance of staying up to date with vaccinations and boosters, particularly for vulnerable populations such as older adults and those with underlying health conditions.
Monitoring and Surveillance
Public health authorities, including the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), are closely monitoring the spread of the Cicada variant. Surveillance methods include wastewater testing and genomic sequencing, which have detected the variant in various states across the U.S. Despite its growing presence, BA.3.2 currently represents a small fraction of total COVID-19 cases in the country.
Criticism and Concerns
While experts acknowledge the potential risks associated with the Cicada variant, they also stress that there is no immediate cause for alarm. Dr. Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, noted, "I have not seen any data which indicates that Cicada is any more severe than other circulating variants." However, the variant's ability to evade immunity warrants ongoing vigilance.
Conclusion: What Lies Ahead
As the Cicada variant continues to spread, health officials remain cautious but not alarmed. The situation underscores the importance of continued public health measures, including vaccination, testing, and monitoring. Experts are particularly focused on whether BA.3.2 will become a dominant strain in the U.S. and how it may influence future COVID-19 trends. Public health authorities urge individuals to maintain basic precautions, such as wearing masks in crowded settings and practicing good hygiene, to mitigate the spread of this and other variants.
